Molecular Cancer Therapeutics
Molecular Cancer Therapeutics publishes the best science in the categories of Therapeutic Discovery, Preclinical Development, and Molecular Medicine in Practice. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
Cancer Apr 19, 2013 | 5 / 5 (2) | 0 |
For the first time, scientists have demonstrated the mechanism of action of gossypin, a naturally-occurring substance found in fruits and vegetables, as a treatment for melanoma, which causes the majority of deaths from skin ...
Cancer Apr 10, 2013 | 5 / 5 (1) | 0
(Medical Xpress)—Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. ...
Cancer Dec 24, 2012 | not rated yet | 0